A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane

Cancer Research and Treatment - South Korea
doi 10.4143/crt.2002.34.4.274
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Cancer Association

Related search

Evolving Approaches to Metastatic Breast Cancer Patients Pre-Treated With Anthracycline and Taxane

BioDrugs
MedicineBiotechnologyPharmacology
2013English

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2006English

A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

A Phase I/Ii Study of GLIF Combination Chemotherapy for Taxane/Platinum-Refractory/Resistant Endometrial Cancer (GOGO-EM2)

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Neoadjuvant Eribulin Mesylate Following Anthracycline and Taxane in Triple Negative Breast Cancer: Results From the HOPE Study

PLoS ONE
Multidisciplinary
2019English

Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Phase II Trial of Gemcitabine and Tanespimycin (17AAG) in Metastatic Pancreatic Cancer: A Mayo Clinic Phase II Consortium Study

Investigational New Drugs
OncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy